Cuprous oxide nanoparticles trigger reactive oxygen species-induced apoptosis through activation of erk-dependent autophagy in bladder cancer
Open Access
- 14 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cell Death & Disease
- Vol. 11 (5), 1-13
- https://doi.org/10.1038/s41419-020-2554-5
Abstract
Cisplatin-based chemotherapy is the first-line treatment for patients with advanced bladder cancer. However, as more than 50% of patients are ineligible for cisplatin-based chemotherapy, there is an urgent need to develop new drugs. Cuprous oxide nanoparticles (CONPs), as a new nano-therapeutic agent, have been proved to be effective in many kinds of tumors. In the present study, CONPs showed dose-dependent and time-dependent inhibitory effects on various bladder cancer cell lines (T24, J82, 5637, and UMUC3) and weak inhibitory effects on non-cancerous epithelial cells (SVHUCs). We found that CONPs induced cell cycle arrest and apoptosis in bladder cancer cells. We further demonstrated that the potential mechanisms of CONP-induced cytotoxicity were apoptosis, which was triggered by reactive oxygen species through activation of ERK signaling pathway, and autophagy. Moreover, the cytotoxic effect of CONPs on bladder cancer was confirmed both in orthotopic xenografts and subcutaneous nude mouse models, indicating that CONPs could significantly suppress the growth of bladder cancer in vivo. In further drug combination experiments, we showed that CONPs had a synergistic drug–drug interaction with cisplatin and gemcitabine in vitro, both of which are commonly used chemotherapy agents for bladder cancer. We further proved that CONPs potentiated the antitumor activity of gemcitabine in vivo without exacerbating the adverse effects, suggesting that CONPs and gemcitabine can be used for combination intravesical chemotherapy. In conclusion, our preclinical data demonstrate that CONPs are a promising nanomedicine against bladder cancer and provide good insights into the application of CONPs and gemcitabine in combination for intravesical bladder cancer treatment.Keywords
Funding Information
- National Natural Science Foundation of China (81772720, 81572509, 81802525, 81801854)
This publication has 52 references indexed in Scilit:
- Cuprous oxide nanoparticles inhibit the growth and metastasis of melanoma by targeting mitochondriaCell Death & Disease, 2013
- The inhibition of human bladder cancer growth by calcium carbonate/CaIP6 nanocomposite particles delivering AIB1 siRNABiomaterials, 2013
- An epirubicin–conjugated nanocarrier with MRI function to overcome lethal multidrug-resistant bladder cancerBiomaterials, 2012
- Cuprous oxide nanoparticles selectively induce apoptosis of tumor cellsInternational Journal of Nanomedicine, 2012
- Full Surface Embedding of Gold Clusters on Silicon Nanowires for Efficient Capture and Photothermal Therapy of Circulating Tumor CellsNano Letters, 2012
- Intravesical gemcitabine therapy for non‐muscle invasive bladder cancer (NMIBC): a systematic reviewBJU International, 2012
- Guidelines for accurate EC50/IC50 estimationPharmaceutical Statistics, 2011
- ERK and cell death: Mechanisms of ERK‐induced cell death – apoptosis, autophagy and senescenceThe FEBS Journal, 2009
- Triphala inhibits both in vitro and in vivo xenograft growth of pancreatic tumor cells by inducing apoptosisBMC Cancer, 2008
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005